Table 1 The information of pairs of genetic alteration-driven genes and drug response genes associated with survival in breast cancer.
Gene pairs | Genetic alterations | Univariate cox analysis | Multivariate cox analysis | ||||||
|---|---|---|---|---|---|---|---|---|---|
P.value a | HR (95%CI) | P.value b | FDR | HR (95%CI) | |||||
PARP1–ACSL1 | |||||||||
Low or High | PARP1: Mutation; copy number amplification; High expression ACSL1: copy number deletion; Low expression | 0.024 | 0.72(0.52–1.004) | 0.021 | 0.042 | 0.68(0.49–0.94) | |||
PARP1–SRD5A3 | |||||||||
Low or High | PARP1: Mutation; copy number amplification; High expression SRD5A3: High expression | 0.0064 | 0.63(0.46–0.8794) | 0.0046 | 0.028 | 0.62(0.45–0.86) | |||
ADIPOR2–SRD5A3 | |||||||||
Low or High | ADIPOR2: copy number amplification; High expression SRD5A3: High expression | 0.0034 | 0.61(0.442–0.8508) | 0.0052 | 0.028 | 0.63(0.45–0.87) | |||
SLC39A11–SRD5A3 | |||||||||
Low or High | SLC39A11: copy number amplification; High expression SRD5A3: High expression | 0.0037 | 0.62(0.4434–0.8544) | 0.0092 | 0.029 | 0.65(0.47–0.90) | |||
B3GALNT2–SRD5A3 | |||||||||
Low or high | B3GALNT2: copy number amplification; High expression SRD5A3: High expression | 0.013 | 0.66(0.4784–0.9172) | 0.011 | 0.029 | 0.65(0.47–0.91) | |||
CASP12–SRD5A3 | |||||||||
Low or High | CASP12: copy number Deletion; Low expression SRD5A3: High expression | 0.01 | 0.65(0.4695–0.9024) | 0.018 | 0.040 | 0.67(0.48–0.93) | |||
CDKN1C–PRLR | |||||||||
Low or High | CDKN1C: DNA Hypermethyation; Low expression PRLR: DNA Hypomethyation; Mutation; High expression | 0.0073 | 0.64(0.4611–0.8864) | 0.019 | 0.031 | 0.67(0.49–0.94) | |||
PODXL2–PRLR | |||||||||
Low or High | PODXL2: DNA Hypomethyation; High expression PRLR: DNA Hypomethyation; Mutation; High expression | 0.015 | 0.67(0.4790.9232) | 0.031 | 0.031 | 0.70(0.50–0.97) | |||
SLC19A1–SLC47A2 | |||||||||
Low or High | SLC19A1: Mutation; High expression SLC47A2: Mutation; Low expression | 0.00035 | 0.54(0.3849–0.7566) | 0.0016 | 0.032 | 0.58(0.41–0.81) | |||
SLC19A1–SRD5A3 | |||||||||
Low or High | SLC19A1: Mutation; High expression SRD5A3: High expression | 0.0021 | 0.59(0.4239–0.8263) | 0.005 | 0.033 | 0.62(0.44–0.86) | |||
AKR1C3–SLC19A1 | |||||||||
Low or high | AKR1C3: Mutation; Low expression SLC19A1: Mutation; High expression | 0.0018 | 0.59(0.4186–0.8199) | 0.0067 | 0.034 | 0.63(0.45–0.88) | |||
ABCB1–SRD5A3 | |||||||||
Low or High | ABCB1:Mutation; Low expression SRD5A3: High expression | 0.0072 | 0.64(0.4615–0.8862) | 0.011 | 0.038 | 0.65(0.47–0.91) | |||
PRLR–SRD5A3 | |||||||||
Low or High | PRLR: DNA Hypomethyation; Mutation; High expression SRD5A3: High expression | 0.012 | 0.66(0.4717–0.91) | 0.012 | 0.038 | 0.66(0.47–0.92) | |||
NR3C2–SRD5A3 | |||||||||
Low or high | NR3C2: Mutation; Low expression SRD5A3: High expression | 0.0024 | 0.60(0.4335–0.8355) | 0.013 | 0.038 | 0.66(0.47–0.92) | |||
AKR1C3–SRD5A3 | |||||||||
Low or high | AKR1C3: Mutation; Low expression SRD5A3: High expression | 0.0079 | 0.64(0.46–0.89) | 0.016 | 0.041 | 0.67(0.48–0.93) | |||
